1. Dage RC, Hsieh CP, Kariya T, Schnettelr RA (1983) Cardiotonic activity of MDL 10,205 <14-ethyl-1.3-dihydro-5-(4-pyridinyl-carbonyl)-2H -imidazol-2 -one> (abstract). Fed Proc 42:1131.
2. Reobel LE, Cheng HC, Woodward JK (1983) Studies on the in vitro and in vivo cardiotonic effects of MDL 19.205 (abstract). Fed Proc 42:1131.
3. Petein M, Levine TB, Cohn JN (1984) Hemodynamic effects of a new inotropic agent, piroximone (MDL 19.205), in patients with chronic heart failure. J Am Coll Cardiol 4:364–371.
4. Axelrod RJ, DeMarco T, Dae M, Botwinik EH, Chatterjee K (1987) Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol 9:1124–1130.
5. Mitrovic V, Schmidt D, Liebrich A, Thormann J, Schlepper M (1991) Hemodynamic and neurohumoral effects of the new phosphodiesterase III inhibitor piroximone in patients with heart failure. Eur Heart J 12(suppl):288.